Are omega-3 fatty acids options for prevention and treatment of cognitive decline and dementia?

Current Opinion in Clinical Nutrition and Metabolic Care

Volumn 13, Issue 2, 2010, Pages 150-155

  Cederholm, Tommy ^a   Palmblad, Jan ^b  

^a UPPSALA UNIVERSITY   (Sweden)

^b KAROLINSKA INSTITUTE   (Sweden)

Author keywords

Alzheimer's disease; Dementia; Docosahexaenoic acid; Omega 3 fatty acids

Indexed keywords

AMYLOID BETA PROTEIN; CYTOKINE; DOCOSAHEXAENOIC ACID; FISH OIL; ICOSAPENTAENOIC ACID; LINOLENIC ACID; OMEGA 3 FATTY ACID; PLACEBO;

ALZHEIMER DISEASE; ANGIOGENESIS; APPETITE; BRAIN PROTECTION; CLINICAL TRIAL; COGNITIVE DEFECT; CONTROLLED CLINICAL TRIAL; DEMENTIA; ENCEPHALITIS; ERYTHROCYTE MEMBRANE; FISH; FOOD INTAKE; HUMAN; NEUROPSYCHOLOGICAL TEST; NONHUMAN; RANDOMIZED CONTROLLED TRIAL; REVIEW; RISK FACTOR; SIGNAL TRANSDUCTION; TREATMENT RESPONSE; WEIGHT CHANGE;

ALZHEIMER DISEASE; ANIMALS; BRAIN; COGNITION; DEMENTIA; DOCOSAHEXAENOIC ACIDS; EICOSAPENTAENOIC ACID; HUMANS; RANDOMIZED CONTROLLED TRIALS AS TOPIC;

EID: 76749152911     PISSN: 13631950     EISSN: 14736519     Source Type: Journal    
DOI: 10.1097/MCO.0b013e328335c40b     Document Type: Review

References (50)

1. Cole G, Ma Q, Frautschy S. Omega-3 fatty acids and dementia. Prostaglandins Leukot Essent Fatty Acids 2009; 81:213-221. An excellent review
2. Riediger N, Othman R, Suh M, Moghadasian M. A systematic review of the roles of n-3 fatty acids in health and disease. J Am Diet Assoc 2009; 109:668-679.
3. Morris M. The role of nutrition in Alzheimer's disease: epidemiological evidence. Eur J Neurology 2009; 16:S1-S7.
4. Calon F, Cole G. Neuroprotective action of omega-3 polyunsaturated fatty acids against neurodegenerative diseases: evidence from animal studies. Prostaglandins Leukot Essent Fatty Acids 2007; 77:287-293.
5. Yehuda S, Rabinovtz S, Carasso RL, Mostofsky DI. Essential fatty acids preparation (SR-3) improves Alzheimer's patients quality of life. Int J Neurosci 1996; 87:141-149.
6. Boston PF, Bennett A, Horrobin DF, Bennett CN. Ethyl-EPA in Alzheimer's disease: a pilot study. Prostaglandins Leukot Essent Fatty Acids 2004; 71:341-346.
7. Kotani S, Sakaguchi E, Warashina S, et al. Dietary supplementation of arachidonic and docosahexaenoic acids improves cognitive dysfunction. Neurosci Res 2006; 56:159-164.
8. Freund Levi Y, Eriksdotter-Jonhagen M, Cederholm T, et al. Omega-3 fatty acid treatment of 174 patients with mild to moderate Alzheimer's disease (OmegAD): a randomized double-blind trial. Arch Neurol 2006; 63:1402-1408.
9. Fotuhi M, Mohassel P, Yaffe K. Fish consumption, long-chain omega-3 fatty acids and risk of cognitive decline or Alzheimer disease: a complex association. Nat Clin Pract Neurol 2009; 5:140-152.
10. Samieri C, Feart C, Letenneur L, et al. Low plasma eicosapentaenoic acid and depressive symptomatology are independent predictors of dementia risk. Am J Clin Nutr 2008; 88:714-721.
11. Kroger E, Verreault R, Carmichael P-H, et al. Omega-3 fatty acids and risk of dementia: the Canadian Study of Health and Aging. Am J Clin Nutr 2009; 90:184-192.
12. Dullemeijer C, Durga J, Brouwer I, et al. N-3 fatty acid proportions in plasma and cognitive performance in older adults. Am J Clin Nutr 2007; 86:1479-1485.
13. Beydoun MA, Kaufman JS, SatiaJA, et al. Plasma n-3 fatty acids and the risk of cognitive decline in older adults: the Atherosclerosis Risk in Communities Study. Am J Clin Nutr 2007; 85:1103-1111.
14. Whalley LJ, Deary IJ, Starr JM, et al. N-3 Fatty acid erythrocyte membrane content, APOE varepsilon4, and cognitive variation: an observational follow-up study in late adulthood. Am J Clin Nutr 2008; 87:449-454.
15. Wang W, Shinto L, Connor WE, Quinn JF. Nutritional biomarkers in Alzheimer's disease: the association between carotenoids, n-3 fatty acids, and dementia severity. J Alzheimers Dis 2008; 13:31-38.
16. Cherubini A, Andres-Lacueva C, Martin A, et al. Low plasma N-3 fatty acids and dementia in older persons: the InCHIANTI study. J Gerontol A Biol Sci Med Sci 2007; 62:1120-1126.
17. Arsenault LN, Matthan N, Scott TM, et al. Validity of estimated dietary eicosapentaenoic acid and docosahexaenoic acid intakes determined by interviewer-administered food frequency questionnaire among older adults with mild-to-moderate cognitive impairment or dementia. Am J Epidemiol 2009; 170:95-103.
18. Barberger-Gateau P, Raffaitin C, Letenneur L, et al. Dietary patterns and risk of dementia: the Three-City cohort study. Neurology 2007; 69:1921-1930.
19. Devore EE, Grodstein F, van Rooij FJ, et al. Dietary intake of fish and omega-3 fatty acids in relation to long-term dementia risk. Am J Clin Nutr 2009;90:170-176.
20. Engelhart MJ, Geerlings MI, Ruitenberg A, et al. Diet and risk of dementia: does fat matter?: the Rotterdam study. Neurology 2002; 59:1915-1921. (Pubitemid 36076564)
21. Kalmijn S, Launer LJ, Ott A, et al. Dietary fat intake and the risk of incident dementia in the Rotterdam Study. Ann Neurol 1997; 42:776-782.
22. van Gelder BM, Tijhuis M, Kalmijn S, Kromhout D. Fish consumption, n-3 fatty acids, and subsequent 5-y cognitive decline in elderly men: the Zutphen Elderly study. Am J Clin Nutr 2007; 85:1142-1147.
23. Albanese E, Dangour A, Uauy R, et al. Dietary fish and meat intake and dementia in Latin America, China, and India: a 10/66 Dementia Research Group population-based study. Am J Clin Nutr 2009; 90:392-400.
24. Dangour AD, Allen E, Elbourne D, et al. Fish consumption and cognitive function among older people in the UK: baseline data from the OPAL study. J Nutr Health Aging 2009; 13:198-202.
25. Nurk E, Drevon CA, Refsum H, et al. Cognitive performance among the elderly and dietary fish intake: the Hordaland Health study. Am J Clin Nutr 2007; 86:1470-1478.
26. van de Rest O, Geleijnse JM, Kok FJ, et al. Effect of fish oil on cognitive performance in older subjects. A randomized, controlled trial. Neurology 2008; 71:430-438.
27. Freund-Levi Y, Basun H, Cederholm T, et al. Omega-3 supplementation in mild to moderate Alzheimer's disease: effects on neuropsychiatric symptoms. Int J Geriatr Psychiatry 2008; 23:161-169.
28. Freund-Levi Y, Hjorth E, Lindberg C, et al. Effects of omega-3 fatty acid on inflammatory markers in CSF and plasma in Alzheimer's disease. The OmegAD study. Dement Geriatr Cogn Disord 2009; 27:481-490.
29. Faxen Irving G, Freund-Levi Y, Eriksdotter-Jonhagen M, et al. N-3 fatty acid supplementation effects on weight and appetite in patients with Alzheimer's disease: the OmegAD Study. J Amer Ger Soc 2009; 57:11-17.
30. Vedin I, Cederholm T, Freund Levi Y, et al. Effects of DHA rich n-3 fatty acid supplementation on cytokine release from blood mononuclear leukocytes. The OmegAD study. Am J Clin Nutr 2008; 87:1616-1622.
31. Chiu CC, Su KP, Cheng TC, et al. The effects of omega-3 fatty acids monotherapy in Alzheimer's disease and mild cognitive impairment: a preliminary randomized double-blind placebo-controlled study. Prog Neuropsy-chopharmacol Biol Psychiatry 2008; 32:1538-1544.
32. Serhan CN, Chiang N, Van Dyke TE. Resolving inflammation: dual antiinflammatory and pro-resolution lipid mediators. Nat Rev Immunol 2008;8:349-361.
33. Serhan CN, Yang R, Martinod K, et al. Maresins: novel macrophage mediators with potent antiinflammatory and proresolving actions. J Exp Med 2009;206:15-23.
34. Musiek ES, Brooks JD, Joo M, et al. Electrophilic cyclopentenone neuropros-tanes are anti-inflammatory mediators formed from the Lukiw WJ, Bazan NG. Docosahexaenoic acid and the aging brain. J Nutr 2008; 138:2510-2514.
35. Belayev L, Khoutorova L, Atkins KD, Bazan NG. Robust docosahexaenoic acid-mediated neuroprotection in a rat model of transient, focal cerebral ischemia. Stroke 2009; 40:3121-3126.
36. Johansson AS, Garlind A, Berglind-Dehlin F, et al. Docosahexaenoic acid stabilizes soluble amyloid-beta protofibrils and sustains amyloid-beta-induced neurotoxicity in vitro. FEBS J 2007; 274:990-1000.
37. Sahlin C, Pettersson FE, Nilsson LN, et al. Docosahexaenoic acid stimulates nonamyloidogenic APP processing resulting in reduced Abeta levels in cellular models of Alzheimer's disease. Eur J Neurosci 2007; 26:882-889.
38. Hossain S, Hashimoto M, Katakura M, et al. Mechanism of docosahexaenoic acid-induced inhibition of in vitro Abeta1-42 fibrillation and Abeta1-42-induced toxicity in SH-S5Y5 cells. J Neurochem 2009; 111:568-579.
39. Hashimoto M, Shahdat HM, Katakura M, et al. Effects of docosahexaenoic acid on in vitro amyloid beta peptide 25-35 fibrillation. Biochim Biophys Acta 2009; 1791:289-296.
40. Katakura M, Hashimoto M, Shahdat HM, et al. Docosahexaenoic acid promotes neuronal differentiation by regulating basic helix-loop-helix transcription factors and cell cycle in neural stem cells. Neuroscience 2009; 160:651-660.
41. Hashimoto M, Hossain S, Tanabe Y, et al. The protective effect of dietary eicosapentaenoic acid against impairment of spatial cognition learning ability in rats infused with amyloid beta(1-40). J Nutr Biochem 2008; 20:965-973.
42. Wurtman RJ, Cansev M, Ulus IH. Synapse formation is enhanced by oral administration of uridine and DHA, the circulating precursors of brain phosphatides. J Nutr Health Aging 2009; 13:189-197.
43. Ma QL, Teter B, Ubeda OJ, et al. Omega-3 fatty acid docosahexaenoic acid increases SorLA/LR11, a sorting protein with reduced expression in sporadic Alzheimer's disease (AD): relevance to AD prevention. J Neurosci 2007; 27:14299-14307.
44. Ma QL, Yang F, Rosario ER, et al. Beta-amyloid oligomers induce phosphorylation of tau and inactivation of insulin receptor substrate via c-Jun N-terminal kinase signaling: suppression by omega-3 fatty acids and curcumin. J Neurosci 2009; 29:9078-9089.
45. Ma QL, Galasko DR, Ringman JM, et al. Reduction of SorLA/LR11, a sortingprotein limiting beta-amyloid production, in Alzheimer disease cerebrospinal fluid. Arch Neurol 2009; 66:448-457.
46. Desai BS, Schneider JA, Li JL, et al. Evidence of angiogenic vessels in Alzheimer's disease. J Neurol Transm 2009; 116:587-597.
47. Patel NS, Quadros A, Brem S, et al. Potent antiangiogenic motifs within the Alzheimer beta-amyloid peptide. Amyloid 2008; 15:5-19.
48. Boscolo E, Folin M, Nico B, et al. Beta amyloid angiogenic activity in vitro and in vivo. Int J Mol Med 2007; 19:581-587.
49. Meyer EP, Ulmann-Schuler A, Staufenbiel M, Krucker T. Altered morphology and 3D architecture of brain vasculature in a mouse model for Alzheimer's disease. Proc Natl Acad Sci USA 2008; 105:3587-3592.
50. Jin Y, Arita M, Zhang Q, et al. Antiangiogenesis effect of the novel antiinflammatory and pro-resolving lipid mediators. Invest Ophthalmol Vis Sci 2009; 50:4743-4752.